Litigation Details for Cubist Pharmaceuticals, Inc. v. Hospira, Inc. (Fed. Cir. 2014)
✉ Email this page to a colleague
Cubist Pharmaceuticals, Inc. v. Hospira, Inc. (Fed. Cir. 2014)
| Docket | ⤷ Try a Trial | Date Filed | 2014-12-18 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | 2015-11-11 |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 6,468,967; 6,852,689; 8,058,238; 8,129,342; RE39,071 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Cubist Pharmaceuticals, Inc. v. Hospira, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Cubist Pharmaceuticals, Inc. v. Hospira, Inc. (Fed. Cir. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-11-11 | 4 | next two are U.S. Patent Nos. 6,852,689 and 6,468,967 (“the ’689 and ’967 patents”), which are entitled…to as the “dosing patents” (the ’967 patent and the ’689 patent) and the two patents that the district…follow-on patents owned by Cubist. The first is U.S. Patent No. RE39,071 (“the ’071 patent”), which …are de- scribed in U.S. Patent No. 4,208,403 (“the ’403 patent”). ’071 patent, col. 6, ll. 59-61; col…referred to as the “purity patents” (the ’238 patent and the ’342 patent). We affirm the district court | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
